| Literature DB >> 24958272 |
André P Fay1, Aymen Elfiky2, Gabriela H Teló3, Rana R McKay4, Marina Kaymakcalan4, Paul L Nguyen2, Anand Vaidya5, Daniel T Ruan2, Joaquim Bellmunt2, Toni K Choueiri6.
Abstract
Adrenocortical cancer is a rare malignancy. While surgery is the cornerstone of the management of localized disease, metastatic disease is hard to treat. Cytotoxic chemotherapy and mitotane have been utilized with a variable degree of benefit and few long-term responses. A growing understanding of the molecular pathogenesis of this malignancy as well as multidisciplinary and multi-institutional collaborative efforts will result in better defined targets and subsequently, effective novel therapies.Entities:
Keywords: Adrenocortical carcinoma; Metastatic disease; Targeted therapies; Therapeutics
Mesh：
Substances：
Year: 2014 PMID： 24958272 PMCID： PMC4578298 DOI： 10.1016/j.critrevonc.2014.05.009
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312